Muller Fabbri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Muller Fabbri has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- George Adrian Calin
The University of Texas MD Anderson Cancer Center
5 shared publications - Ivan Vannini
Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
4 shared publications - Nicola Valeri
Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom
4 shared publications - Alessio Paone
Department of Biochemical Sciences A. Rossi Fanelli, Sapienza University of Rome, Rome, Italy
3 shared publications - Carlo Maria Croce
Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA
3 shared publications - Francesca Fanini
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l., Meldola 47014, FC, Italy; Istituto Oncologico Romagnolo Coop. Soc. ONLUS, Forlì 47121, FC, Italy
3 shared publications
Latest Publications
- 21 May 2012
- Published by Springer Nature
- p. 573-587
Noncoding RNAs: Identification of Cancer-Associated MicroRNAs
- 21 May 2012
- Published by Springer Nature
- p. 573-587
Noncoding RNAs: Identification of Cancer-Associated MicroRNAs
- 1 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (4) , 457
Anti-miR-135b in colon cancer treatment: Results from a preclinical study.
457 Background: MicroRNAs (miRs) are small non coding RNAs involved in cell homeostasis. miRs are deregulated in colorectal cancer (CRC). Our study aimed at identifying miRs with a driver role in carcinogenesis altered by similar mechanisms in both human and mouse CRC. Goal of the study was to use CRC mouse models for the pre-clinical development of anti-miRs as therapeutic drugs. Methods: Azoximetane (AOM)/Dextran-Sulfate (DSS) treated mice or CDX2-CRE/APC-/- mice were used to study inflammation-associated and sporadic APC-related CRC. Human Inflammatory Bowel Disease associated (n=30), and sporadic (n=90) CRC with their matched normal tissues were collected according to Good Clinical Practice recommendation and subjected to RNA extraction using Trizol. miR and gene expression profiling was assessed by nCounter technology (Nanostring Seattle). Anti-miR-135b and scrambled probes for in vivo studies were synthesized by Girindus. Results: miRs profiling from AOM/DSS and CDX2-CRE/APC-/- CRC. revealed that miR-135b is one of the most up-regulated miRs in both models. In humans miR-135b over-expression was found in both IBD and sporadic CRC and was associated with reduced Progression Free Survival and Overall Survival in CRC patients. Molecular studies in Mouse Embryo Fibroblast and human CRC cell lines highlighted the role of two major pathways in the upstream activation of miR-135b: APC-β-Catenin and SRC-PI3K. MiR-135b up-regulation resulted in reduced apoptosis and increased invasion and metastasis due to the down-regulation of TGFRB2, DAPK1, APC and HIF1AN. Silencing of miR-135b in vivo reduced tumor multiplicity and tumor load in the AOM/DSS CRC model. Mice treated with anti-miR-135b showed well differentiated tumors and microacinar pattern while tumors in the control groups showed low differentiation and adenomatous pattern. Conclusions: Our data suggest that miR-135b is a key molecule whose activation is downstream of oncogenes and oncosuppressor genes frequently altered in CRC. Our study defines specific pathways that converge on the activation of the same microrna. The “in vivo” silencing of miR-135 shows preclinical efficacy with low toxicity and represents the first in vivo study for the use of antimiRs in CRC treatment.
- 1 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (4) , 457
Anti-miR-135b in colon cancer treatment: Results from a preclinical study.
457 Background: MicroRNAs (miRs) are small non coding RNAs involved in cell homeostasis. miRs are deregulated in colorectal cancer (CRC). Our study aimed at identifying miRs with a driver role in carcinogenesis altered by similar mechanisms in both human and mouse CRC. Goal of the study was to use CRC mouse models for the pre-clinical development of anti-miRs as therapeutic drugs. Methods: Azoximetane (AOM)/Dextran-Sulfate (DSS) treated mice or CDX2-CRE/APC-/- mice were used to study inflammation-associated and sporadic APC-related CRC. Human Inflammatory Bowel Disease associated (n=30), and sporadic (n=90) CRC with their matched normal tissues were collected according to Good Clinical Practice recommendation and subjected to RNA extraction using Trizol. miR and gene expression profiling was assessed by nCounter technology (Nanostring Seattle). Anti-miR-135b and scrambled probes for in vivo studies were synthesized by Girindus. Results: miRs profiling from AOM/DSS and CDX2-CRE/APC-/- CRC. revealed that miR-135b is one of the most up-regulated miRs in both models. In humans miR-135b over-expression was found in both IBD and sporadic CRC and was associated with reduced Progression Free Survival and Overall Survival in CRC patients. Molecular studies in Mouse Embryo Fibroblast and human CRC cell lines highlighted the role of two major pathways in the upstream activation of miR-135b: APC-β-Catenin and SRC-PI3K. MiR-135b up-regulation resulted in reduced apoptosis and increased invasion and metastasis due to the down-regulation of TGFRB2, DAPK1, APC and HIF1AN. Silencing of miR-135b in vivo reduced tumor multiplicity and tumor load in the AOM/DSS CRC model. Mice treated with anti-miR-135b showed well differentiated tumors and microacinar pattern while tumors in the control groups showed low differentiation and adenomatous pattern. Conclusions: Our data suggest that miR-135b is a key molecule whose activation is downstream of oncogenes and oncosuppressor genes frequently altered in CRC. Our study defines specific pathways that converge on the activation of the same microrna. The “in vivo” silencing of miR-135 shows preclinical efficacy with low toxicity and represents the first in vivo study for the use of antimiRs in CRC treatment.
- 8 January 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (2 Suppleme) , B14
Abstract B14: Anti-miR-135b in colon cancer treatment
Background: MicroRNAs (miRs) are small non coding RNAs involved in cell homeostasis. miRs are deregulated in colorectal cancer (CRC). Our study aimed at identifying miRs with a driver role in carcinogenesis altered by similar mechanisms in both human and mouse CRC. Goal of the study was to use CRC mouse models for the pre-clinical development of anti-miRs as therapeutic drugs. Methods: Azoximetane (AOM)/Dextran-Sulfate (DSS) treated mice or CDX2Cre-APC f/wt mice were used to study inflammation-associated and sporadic APC-related CRC. Human Inflammatory Bowel Disease associated (n=30), and sporadic (n=90) CRC with their matched normal tissues were collected according to Good Clinical Practice recommendation and subjected to RNA extraction using Trizol. miR and gene expression profiling was assessed by nCounter technology (Nanostring Seattle). AntimiR-135b and scrambled probes for in vivo studies were synthesized by Girindus. Results: miRs profiling from AOM/DSS and CDX2Cre-APC f/wt CRC. revealed that miR-135b is one of the most up-regulated miRs in both models. In humans miR-135b over-expression was found in both IBD and sporadic CRC and was associated with reduced Progression Free Survival and Overall Survival in CRC patients. Molecular studies in Mouse Embryo Fibroblast and human CRC cell lines highlighted the role of two major pathways in the upstream activation of miR-135b: APC-β-Catenin and SRC-PI3K. MiR-135b up-regulation resulted in reduced apoptosis and increased invasion and metastasis due to the down-regulation of TGFRB2, DAPK1, APC and HIF1AN. Silencing of miR-135b in vivo reduced tumor multiplicity and tumor load in the AOM/DSS CRC model. Mice treated with anti-miR-135b showed well differentiated tumors and acinar pattern while tumors in the control groups showed low differentiation and adenomatous pattern. Conclusions: Our data suggest that miR-135b is a key molecule whose activation is downstream of oncogenes and oncosuppressor genes frequently altered in CRC. Our study defines specific pathways that converge on the activation of the same microrna. The “in vivo” silencing of miR-135 shows preclinical efficacy with low toxicity and represents the first in vivo study for the use of antimiRs in CRC treatment Note: This abstract was not presented at the conference because the presenter was unable to attend. Citation Format: Nicola Valeri, Roberta Gafa', Gerard Nuovo, Giovanni Lanza, Wendy Frankel, Peter K. Vogt, Joanna Groden, Michael Karin, Carlo M. Croce, Chiara Braconi, Pierluigi Gasparini, Sergei Grivennikov, Jonathan R. Hart, Alessio Paone, Francesca Lovat, Muller Fabbri. Anti-miR-135b in colon cancer treatment [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer; 2012 Jan 8-11; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(2 Suppl):Abstract nr B14.
- 8 January 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (2 Suppleme) , B14
Abstract B14: Anti-miR-135b in colon cancer treatment
Background: MicroRNAs (miRs) are small non coding RNAs involved in cell homeostasis. miRs are deregulated in colorectal cancer (CRC). Our study aimed at identifying miRs with a driver role in carcinogenesis altered by similar mechanisms in both human and mouse CRC. Goal of the study was to use CRC mouse models for the pre-clinical development of anti-miRs as therapeutic drugs. Methods: Azoximetane (AOM)/Dextran-Sulfate (DSS) treated mice or CDX2Cre-APC f/wt mice were used to study inflammation-associated and sporadic APC-related CRC. Human Inflammatory Bowel Disease associated (n=30), and sporadic (n=90) CRC with their matched normal tissues were collected according to Good Clinical Practice recommendation and subjected to RNA extraction using Trizol. miR and gene expression profiling was assessed by nCounter technology (Nanostring Seattle). AntimiR-135b and scrambled probes for in vivo studies were synthesized by Girindus. Results: miRs profiling from AOM/DSS and CDX2Cre-APC f/wt CRC. revealed that miR-135b is one of the most up-regulated miRs in both models. In humans miR-135b over-expression was found in both IBD and sporadic CRC and was associated with reduced Progression Free Survival and Overall Survival in CRC patients. Molecular studies in Mouse Embryo Fibroblast and human CRC cell lines highlighted the role of two major pathways in the upstream activation of miR-135b: APC-β-Catenin and SRC-PI3K. MiR-135b up-regulation resulted in reduced apoptosis and increased invasion and metastasis due to the down-regulation of TGFRB2, DAPK1, APC and HIF1AN. Silencing of miR-135b in vivo reduced tumor multiplicity and tumor load in the AOM/DSS CRC model. Mice treated with anti-miR-135b showed well differentiated tumors and acinar pattern while tumors in the control groups showed low differentiation and adenomatous pattern. Conclusions: Our data suggest that miR-135b is a key molecule whose activation is downstream of oncogenes and oncosuppressor genes frequently altered in CRC. Our study defines specific pathways that converge on the activation of the same microrna. The “in vivo” silencing of miR-135 shows preclinical efficacy with low toxicity and represents the first in vivo study for the use of antimiRs in CRC treatment Note: This abstract was not presented at the conference because the presenter was unable to attend. Citation Format: Nicola Valeri, Roberta Gafa', Gerard Nuovo, Giovanni Lanza, Wendy Frankel, Peter K. Vogt, Joanna Groden, Michael Karin, Carlo M. Croce, Chiara Braconi, Pierluigi Gasparini, Sergei Grivennikov, Jonathan R. Hart, Alessio Paone, Francesca Lovat, Muller Fabbri. Anti-miR-135b in colon cancer treatment [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer; 2012 Jan 8-11; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(2 Suppl):Abstract nr B14.
- 1 December 2011
- Published by Elsevier in Seminars in Oncology
- Vol. 38 (6) , 776-780
Clinical Implications of MicroRNAs in Lung Cancer
- 1 December 2011
- Published by Elsevier in Seminars in Oncology
- Vol. 38 (6) , 776-780
Clinical Implications of MicroRNAs in Lung Cancer
- 1 October 2011
- Published by Springer Nature in Frontiers in Biology
- Vol. 6 (5) , 351-356
MicroRNAs and drug modulation in cancer: an intertwined new story
- 1 October 2011
- Published by Springer Nature in Frontiers in Biology
- Vol. 6 (5) , 351-356
MicroRNAs and drug modulation in cancer: an intertwined new story
- Open Access
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 2, 12941
MicroRNAs as New Characters in the Plot between Epigenetics and Prostate Cancer
Prostate cancer (PCA) still represents a leading cause of death. An increasing number of studies have documented that microRNAs (miRNAs), a subgroup of non-coding RNAs with gene regulatory functions, are differentially expressed in PCA respect to the normal tissue counterpart, suggesting their involvement in prostate carcinogenesis and dissemination. Interestingly, it has been shown that miRNAs undergo the same regulatory mechanisms than any other protein coding gene, including epigenetic regulation. In turn, miRNAs can also affect the expression of oncogenes and tumor suppressor genes by targeting effectors of the epigenetic machinery, therefore indirectly affecting the epigenetic controls on these genes. Among the genes that undergo this complex regulation, there is the androgen receptor (AR), a key therapeutic target for PCA. This review will focus on the role of epigenetically regulated and epigenetically regulating miRNAs in PCA and on the fine regulation of AR expression, as mediated by this miRNA–epigenetics interaction.
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 2, 12941
Open AccessMicroRNAs as New Characters in the Plot between Epigenetics and Prostate Cancer
Prostate cancer (PCA) still represents a leading cause of death. An increasing number of studies have documented that microRNAs (miRNAs), a subgroup of non-coding RNAs with gene regulatory functions, are differentially expressed in PCA respect to the normal tissue counterpart, suggesting their involvement in prostate carcinogenesis and dissemination. Interestingly, it has been shown that miRNAs undergo the same regulatory mechanisms than any other protein coding gene, including epigenetic regulation. In turn, miRNAs can also affect the expression of oncogenes and tumor suppressor genes by targeting effectors of the epigenetic machinery, therefore indirectly affecting the epigenetic controls on these genes. Among the genes that undergo this complex regulation, there is the androgen receptor (AR), a key therapeutic target for PCA. This review will focus on the role of epigenetically regulated and epigenetically regulating miRNAs in PCA and on the fine regulation of AR expression, as mediated by this miRNA–epigenetics interaction.
- 19 August 2010
- Published by Springer Nature
- Vol. 667, 79-91
High-Throughput Profiling in the Hematopoietic System
The expression profile of microRNAs significantly varies in physiological and pathological conditions. Increasing evidence from the literature shows that abnormalities of the miRNome (defined as the full spectrum of miRNAs expressed in a genome) occur in almost all human diseases and have important pathogenetic, prognostic, and therapeutic implications. The study of the aberrancies of the miRNome has become possible by developing high-throughput profiling techniques that allow the simultaneous detection of differences in miRNA expression between normal and pathologic tissues or simply tissues at different stages of differentiation. These techniques provide the basis for further investigations focused on the miRNAs, which are most frequently and widely differentially expressed under the different investigated conditions.
- 19 August 2010
- Published by Springer Nature
- Vol. 667, 79-91
High-Throughput Profiling in the Hematopoietic System
The expression profile of microRNAs significantly varies in physiological and pathological conditions. Increasing evidence from the literature shows that abnormalities of the miRNome (defined as the full spectrum of miRNAs expressed in a genome) occur in almost all human diseases and have important pathogenetic, prognostic, and therapeutic implications. The study of the aberrancies of the miRNome has become possible by developing high-throughput profiling techniques that allow the simultaneous detection of differences in miRNA expression between normal and pathologic tissues or simply tissues at different stages of differentiation. These techniques provide the basis for further investigations focused on the miRNAs, which are most frequently and widely differentially expressed under the different investigated conditions.
- 19 July 2010
- Published by Springer Nature
- p. 325-340
Micro-RNAs in Hematologic Malignancies
- 1 May 2010
- Vol. 13 (3) , 350-8
Beyond genomics: interpreting the 93% of the human genome that does not encode proteins.
The traditional understanding that proteins are the only effectors of gene function has been challenged by the discovery of a group of genes that do not encode proteins (non-coding genes [ncGs]). The role of ncGs in the pathogenesis and potentially the treatment of several human diseases is increasingly being confirmed. A robust collection of literature exists to support the theory of the involvement of ncGs and their non-coding RNA (ncRNA) transcripts in the pathogenesis of cancer. This review focuses on the role of ncRNAs in human carcinogenesis and describes why deciphering the function of these RNAs might lead to the development of new anticancer drugs.
- 1 May 2010
- Vol. 13 (3) , 350-8
Beyond genomics: interpreting the 93% of the human genome that does not encode proteins.
The traditional understanding that proteins are the only effectors of gene function has been challenged by the discovery of a group of genes that do not encode proteins (non-coding genes [ncGs]). The role of ncGs in the pathogenesis and potentially the treatment of several human diseases is increasingly being confirmed. A robust collection of literature exists to support the theory of the involvement of ncGs and their non-coding RNA (ncRNA) transcripts in the pathogenesis of cancer. This review focuses on the role of ncRNAs in human carcinogenesis and describes why deciphering the function of these RNAs might lead to the development of new anticancer drugs.
- 1 May 2010
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 10 (4) , 435-444
miRNAs as molecular biomarkers of cancer
MiRNAs are noncoding RNAs that regulate gene expression. The advent of high-throughput techniques has revealed that miRNA expression is deregulated in almost all human tumors (both solid and hematologic) with respect to the normal tissue counterpart. These differences frequently recur in tumor-specific miRNA signatures, which are very helpful to diagnose the tissue of origin of the neoplasia, and sometimes also specific tumor subtypes. Increasing evidence also supports a role for miRNAs as prognostic biomarkers of human cancers. Finally, miRNAs are differentially expressed in the blood of cancer patients versus healthy donors, providing a rationale for the detection of miRNAs and diagnostic and prognostic circulating biomarkers.
- 1 May 2010
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 10 (4) , 435-444
miRNAs as molecular biomarkers of cancer
MiRNAs are noncoding RNAs that regulate gene expression. The advent of high-throughput techniques has revealed that miRNA expression is deregulated in almost all human tumors (both solid and hematologic) with respect to the normal tissue counterpart. These differences frequently recur in tumor-specific miRNA signatures, which are very helpful to diagnose the tissue of origin of the neoplasia, and sometimes also specific tumor subtypes. Increasing evidence also supports a role for miRNAs as prognostic biomarkers of human cancers. Finally, miRNAs are differentially expressed in the blood of cancer patients versus healthy donors, providing a rationale for the detection of miRNAs and diagnostic and prognostic circulating biomarkers.